AstraZeneca eyes merger with Gilead Sciences - the stock is under pressure

AstraZeneca, the pharmaceutical group, has approached U.S. rival Gilead Sciences regarding a potential merger, reported Bloomberg citing people familiar with the matter.

Stocks (2)

AstraZeneca, the pharmaceutical group, has approached U.S. rival Gilead Sciences regarding a potential merger, reported Bloomberg citing people familiar with the matter.
The merger of the two groups would create a giant with a market capitalization of $230 billion.

An AstraZeneca spokesperson said the group did not comment on rumors or assumptions. Gilead did not wish to comment.

Gilead is particularly active in the treatment of HIV with its drug Biktarvy, which had sales of $1.69 billion in the first quarter.

AstraZeneca also has Tagrisso, a treatment for lung cancer, which generated $982 million in sales in the first three months of the year.

From a chartist's point of view, AstraZeneca escaped from a short term bullish channel and entered into a consolidation move. The daily Relative strength Index (RSI, 14) fell below 50% and is capped by a declining trend line. Bollinger bands are widening. 

As long as 8811p is resistance, a decline towards 8046p and 7685p is likely. Alternatively, a push above 8811p would reinstate a bullish bias with 9600p as target.

Source: GAIN Capital, TradingView


More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.